Arch Pharmalabs Ltd
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE -4.12 %
- ROE -39.3 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -10.3% over past five years.
- Company has a low return on equity of -18.5% over last 3 years.
- Company has high debtors of 911 days.
- Working capital days have increased from 674 days to 1,485 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|---|---|---|---|
| 539 | 981 | 1,162 | 1,425 | 1,771 | 2,265 | 569 | |
| 437 | 805 | 897 | 1,077 | 1,321 | 2,016 | 626 | |
| Operating Profit | 102 | 176 | 264 | 348 | 450 | 248 | -57 |
| OPM % | 19% | 18% | 23% | 24% | 25% | 11% | -10% |
| 4 | 0 | 7 | 6 | 22 | 13 | 2 | |
| Interest | 38 | 82 | 143 | 167 | 242 | 307 | 332 |
| Depreciation | 18 | 33 | 52 | 66 | 84 | 96 | 104 |
| Profit before tax | 50 | 61 | 76 | 122 | 146 | -141 | -491 |
| Tax % | 28% | 30% | 27% | 29% | 27% | 10% | -13% |
| 35 | 43 | 56 | 87 | 106 | -154 | -428 | |
| EPS in Rs | |||||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -10% |
| 3 Years: | -26% |
| TTM: | -75% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -161% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -9% |
| 3 Years: | -19% |
| Last Year: | -39% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 25 | 25 | 28 | 28 |
| Reserves | 325 | 362 | 443 | 650 | 750 | 751 | 1,307 |
| 420 | 954 | 1,248 | 1,382 | 1,615 | 2,386 | 3,145 | |
| 103 | 257 | 322 | 441 | 678 | 847 | 472 | |
| Total Liabilities | 869 | 1,594 | 2,035 | 2,498 | 3,067 | 4,012 | 4,952 |
| 301 | 529 | 645 | 768 | 848 | 921 | 1,795 | |
| CWIP | 32 | 135 | 97 | 30 | 63 | 34 | 31 |
| Investments | 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| 518 | 930 | 1,293 | 1,699 | 2,156 | 3,057 | 3,125 | |
| Total Assets | 869 | 1,594 | 2,035 | 2,498 | 3,067 | 4,012 | 4,952 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|---|---|---|---|
| -183 | -17 | 187 | 239 | -447 | -511 | ||
| -339 | -132 | -262 | -187 | -150 | -2 | ||
| 466 | 169 | 77 | -25 | 630 | 426 | ||
| Net Cash Flow | -55 | 20 | 1 | 27 | 33 | -86 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 111 | 132 | 168 | 153 | 152 | 189 | 911 |
| Inventory Days | 180 | 204 | 217 | 213 | 211 | 215 | 672 |
| Days Payable | 80 | 53 | 111 | 144 | 179 | 148 | 279 |
| Cash Conversion Cycle | 212 | 283 | 275 | 222 | 184 | 256 | 1,304 |
| Working Capital Days | 229 | 257 | 307 | 282 | 239 | 299 | 1,485 |
| ROCE % | 14% | 14% | 15% | 17% | 6% | -4% |
Documents
Announcements
No data available.
Annual reports
No data available.